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ABSTRACT
Background: To investigate the contribution of right ventricular (RV) pacing sites to the cardiac function, this 
study compares plasma B-type natriuretic peptide (BNP) levels during RV septal and apical pacing in patients 
implanted with a pacemaker. Materials and Methods and Results: Seventy-four consecutive patients with 
indication for permanent pacing were included. To provide for the possibility of appropriate subgroup analyses, 
patients were stratified according to their pacing mode into two groups: Those with dual chamber DDD(R)/
VDD pacemakers (41 patients, mean age 54.1±18.4 years), and those with single chamber VVI pacemakers (33 
patients, mean age 60.6±18.4 years). A prospective single-blinded randomized design was used. Randomization 
(1:1 way) was between lead placement on the RV septum or RV apex and occurred during the implant in 
both groups. Compared to baseline, a significant decrease in BNP (429.8±103 pg/ml and 291.7±138 pg/ml, 
respectively) levels was observed during DDD(R) /VDD pacing after two months. In contrast, during VVI (R) 
pacing, a significant increase in BNP levels was observed (657.5±104 pg/ml and 889.5±139 pg/ml, respectively). 
To determine the impact of pacing sites on cardiac function, we assessed the changes in BNP levels in each 
group separately. Despite the significant difference in the pattern of changes between the two groups (P < 0.02), 
no significant changes were observed within groups regarding the acute effect of the pacing site (RV apex vs. 
RV septal) on BNP levels (P=NS). Conclusions: Our main result showed no significant differences between 
pacing sites and concluded that hemodynamic improvement could be substantially influenced by pacing mode, 
more than by pacing site.
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INTRODUCTION
Several clinical and experimental studies have suggested that 
long-term right ventricular (RV) apical pacing deteriorates 
left ventricular (LV) function. They have demonstrated the 
deleterious consequences of intraventricular conduction 
delay, particularly those produced by left bundle branch 
block (LBBB).[1–7]Alternative sites were tested with a 
view to optimize or stabilize LV function. Septal pacing 
seemed to better preserve cardiac performance in patients 
with normal LV systolic function,[8,9] however, its effects 
in patients with preexistent LV systolic dysfunction are 
unknown. Neurohumoral factors represent the natural 
response of the individual to heart failure. Among them 
natriuretic peptides, especially B-type natriuretic peptides 
(BNP), have been shown to be reliable and rapid markers 
for diagnosis in heart failure patients. BNP, which is 
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released primarily in response to increased atrial and 
ventricular stress, is a marker of the severity of heart 
failure. Furthermore, BNP levels reflect hemodynamic 
changes elicited by different pacing modes, and BNP levels 
are significantly higher during asynchronous ventricular 
pacing than during atrioventricular sequential pacing.[10-12]It 
has been reported that BNP levels will change in patients 
with permanent cardiac pacing;[10-13] nevertheless, in fact, we 
do not exactly know how BNP levels change in different 
pacing sites, and we do not accurately know if RV septal 
pacing can really reduce BNP levels.
The primary objective of the present study was to 
demonstrate that RV septal pacing would better preserve 
ventricular function than RV apical pacing. The primary 
outcome measure is the change in BNP level at the end of 
the two-month follow-up period.
MATERIALS AND METHODS
Study population
Seventy-four consecutive patients with indications for 
permanent pacing were enrolled into the present study. 
Patients were implanted with either a dual or single-
chamber pacemaker depending on whether the patient 
was in sinus rhythm or permanent atrial tachyarrhythmia. 
Exclusion criteria were symptomatic heart failure and any 
form of acute coronary syndrome within the previous 
month. During follow-up, patients were excluded if they 
had inadequate pacing lead position, or < 90% ventricular 
pacing (n=9).
To provide for the possibility of appropriate subgroup 
analyses, patients were stratified according to their 
pacing mode into two groups: Those with DDD/VDD 
pacemakers and those with VVI pacemakers. Group 
I consisted of 33 patients with implanted VVI (R) 
pacemakers (mean age 60.6 ± 18.4 years) and Group II had 
41 patients with DDD (R)/VDD pacemakers (mean age 
54.1 ± 18 years). The hospital Ethical Committee approved 
the present study and all patients gave written informed 
consent prior to enrollment into the study.
Study design
A prospective single-blinded randomized design was used 
in both groups. Randomization (1:1 way) was between lead 
placement on the RV septum or RV apex and occurred 
during the implant. An implanted RV pacing lead was 
implanted at the RV septal position or RV apex using any 
commercially available active fixation lead via an axillary 
or subclavian puncture and in the case of dual-chamber 
pacemakers, an active atrial lead was fixed for the right 
appendage. The procedure for implantation of the RV 
septal lead was defined in the study protocol as to be 
performed by advancing the lead out the pulmonary artery, 
withdrawing the lead until it dropped below the pulmonic 
valve, and then advancing the lead into the high septum. 
The distal electrode was placed at the junction between the 
upper and middle septal segments, in a position to obtain 
the shortest pace-mapped QRS. Proper lead positioning 
was confirmed by multiple fluoroscopic views and surface 
electrocardiogram ECG.
Post-implantation chest X-ray and ECGs were given to 
confirm appropriate lead positions. The lower and upper 
pacing rate limits and sensor settings were individually 
programmed according to patient needs. All the implanted 
RV pacing leads were positioned at a stable position to 
obtain a satisfactory pacing threshold value (mean: 1.3 ± 
0.7 V, at a pulse width of 0.5 ms). All study patients had 
successful device replacement procedure without any 
complication.
Among patients with VVI pacemakers, the final positions 
of the RV leads were at the septum in 15 patients and at the 
RV apex in 18; in patients with DDD/VDD pacemakers 
the final lead positions were at the septum in 24 and at the 
RV apex in 17.
Plasma samples for the determination of plasma BNP were 
drawn before and two months after pacemaker implantation.
B-type natriuretic peptide measurement
Venous blood was taken from an antecubital vein in gel-
filled tubes after the patient had been in a supine position 
for at least 15 min. At randomization and at the end of 
each study period, a venous blood sample was collected 
in tubes containing potassium Ethylenediaminetetraacetic 
acid EDTA. Specimens were centrifuged at 3000 rpm (15ºC 
for 10 min) and separated plasma was immediately assayed. 
All samples were plasma natriuretic peptide concentrations 
were measured with a specific immunoradiometric assay 
for human BNP using a highly sensitive, commercially 
available, enzyme-linked immunoassay (Biomedica Gruppe, 
Austria) and reported in pg/ml.
Statistical analysis
Continuous data are expressed as mean ± SE. A paired 
Student’s t test analysis was used for comparison within 
groups and a non-specified Student’s t test analysis for 
comparison between groups; all were done as two-sided 106 Journal of Cardiovascular Disease Research Vol. 2 / No 2
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tests. Categorical variables were compared by Chi-square 
analysis or Fisher’s exact tests and summarized by 
proportion in each category. Covariance analyses were 
used to compare variables between the two groups with 
adjustment for the pre-pacing values of these variables. 
We compared clinical characteristics including BNP levels 
between two groups using the X2 and Mann-Whitney U 
tests. Factors associated with BNP levels were examined 
using the Mann-Whitney U test and linear regression 
analysis. Factors with a probability of <0.1 on univariate 
analysis were entered into a multivariate analysis. All 
statistical analyses were completed using the SPSS 15 
software package. A two-sided P< 0.05 was considered 
statistically significant.
RESULTS
The baseline characteristics of patients are shown in 
Table 1. To provide for the possibility of appropriate 
subgroup analyses, patients were divided according to 
their pacing mode into two groups after randomization: 
those with DDD/VDD(R) pacemakers and those with 
VVI (R) pacemakers. Group I consisted of 33 patients 
with implanted VVI (R)pacemakers (mean age 60.6 ± 
18.4 years, 15 men) and Group II had 41 patients with 
DDD/VDD (R)pacemakers (mean age 54.1 ± 18 years, 
16 men). The primary implant indication was sick sinus 
syndrome in 14 patients, high-degree atrioventricular 
AV block in 35 patients, and a combination of these 
two disorders in 25 patients. The telemetrically assessed 
percentage of ventricular paced beats was 98±0.3% in 
the DDD /VDD(R) mode and 98±0.8% in the VVI (R) 
mode (P=NS).
There was no significant difference in the age, gender 
distribution, percentage of ventricular pacing and QRS 
duration before implantation, the medications, hypertension, 
diabetes and coronary artery diseases between groups. 
Compared to baseline, a significant decrease in BNP 
(429.8±103 pg/ml and 291.7±138 pg/ml, respectively) 
levels was observed during DDD/VDD (R) pacing after 
two months. In contrast, during VVI (R) pacing, a significant 
increase in BNP levels was observed (657.5±104 pg/ml and 
889.5±139 pg/ml, respectively) [Figure 1]. 
Table 2 shows the important characteristics of the study 
subgroups according to pacing site (RV apex group and 
RV septal group).
In Group I, 18 patients were randomized to RV apex 
pacing and 15 to septal pacing. In Group II, 17 patients 
were randomized to RVA pacing and 24 to RV septal 
pacing. To determine the impact of pacing sites on 
Figure 1: Plasma concentrations of BNP in patients with a VVI pacing 
mode compared with DDD mode
Table 2: Characteristics of the study subgroups according 
to pacing site (RVA group and RV septal group)
DDD (R )/VDD VVI (R )
RV 
septal
RVA RV 
septal
RVA
Age (year) 56.3 ± 19 51.1 ± 16 58 ± 21 64 ± 13
Male sex (n) 9 7 5 10
Ejection 
fraction(%)
54.2 ± 10 48.7 ± 8.6   48.5 ± 13 50.7 ± 13
LA size (mm) 40.0 ± 3.7 51.1 ± 16 40.1 ± 5 43.4 ± 5
Functional  
class (n)    
NYHA I 16 11 11 13
NYHA II 8 6 4 5
Primary implant 
indication (n) 
Sinoatrial nodal 
disease
2 1 6 5
Atrioventricular 
nodal disease
13 10 5 7
Combination of 
both
9 6 4 6
Table 1: Baseline characteristics
Age (year) 57.2 ± 18
Male sex (n) 31
Type of pacemaker (n)
DDD( R )/VDD  41
VVI ( R ) 33
Functional class (n)
NYHA I 51
NYHA II 23
Primary implant indication (n)
Sinoatrial nodal disease 14
Atrioventricular nodal disease 35
Combination of both 25107 Journal of Cardiovascular Disease Research Vol. 2 / No 2
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cardiac function, we assessed the changes in BNP levels 
in each group separately. Table 3 shows the association 
between BNP levels and pacing sites (RV apex vs. RV 
septal). The result was a significant difference in the 
pattern of changes between the two groups [P < 0.02, 
Figure 1]; nevertheless, no significant changes were 
observed within groups regarding the acute effect of 
pacing site (RV apex vs. RV septal) on BNP levels   
[Figure 2a and 2b](P=NS).
This pattern of change in the BNP level was consistently 
present using multivariate analysis while considering 
confounding factors such as sex, age, left ventricular 
ejection fraction LVEF, and different pacing indications.
Despite the increase in BNP levels in patients with the 
VVI mode, compared with those with the DDD(R) / 
VDD mode, the pacing sites had no effect on BNP levels, 
irrespective of the pacing mode.
In Group I, 12 patients were randomized to RV apex 
pacing and 16 to septal pacing. In Group II, 13 patients 
were randomized to RVA pacing and 17to RV septal 
pacing. To determine the impact of pacing sites on cardiac 
function, we assessed the changes in BNP levels in each 
group separately. Table 3 shows the association between 
BNP levels and pacing sites (RV apex vs. RV septal). 
The result was a significant difference in the pattern of 
changes between the two groups [P< 0.02, see Figure 1]; 
nevertheless, no significant changes were observed within 
groups regarding the acute effect of the pacing site (RV 
apex vs. RV septal) on BNP levels [Figure 2](P=NS).
This pattern of change in the BNP level was consistently 
present using multivariate analysis while considering 
confounding factors such as sex, age, LVEF, and different 
pacing indications. 
Despite the increase in BNP levels in patients with the 
VVI mode compared with those with DDD(R) /VDD 
mode, the pacing sites had no effect on the BNP levels, 
irrespective of the pacing mode.
DISCUSSION
Evidence-based clinical trials in cardiac pacing designed 
to determine the most physiologic pacing mode have 
shown an increased risk of heart failure and/or mortality 
associated with chronic RVA pacing independent of the 
pacing mode.[2,3]Although several studies have investigated 
the acute and chronic effects of pacing from alternative 
RV sites outside of the apex, the optimal RV pacing 
lead location for patients with a standard indication for 
ventricular pacing, remains controversial.[14-16] Even though 
data suggest that RV septal pacing is not inferior to RVA 
pacing, the clinical benefits of pacing from alternative RV 
sites have not yet been established.[8,9,17-19]Victor et al.,[20] did 
not find significant differences between RV apex and right 
ventricular outflow tract RVOT pacing after three months 
with respect to functional class, LVEF, duration of exercise 
and maximum oxygen uptake. Similar results come from 
Figure 2(a and b): The changes observed within groups regarding the acute effect of pacing site (RV apex vs. RV septal) on BNP levels
Table 3: BNP levels ( pg/ml) according to pacing site 
(Subgroup analysis)
Septal  
pacing
RVA  
pacing
P valve
DDD (R)/VDD
Pre 494.9 ± 296 310.9 ± 292 P=0.07
Post 367.4 ± 417 288.4 ± 289
VVI (R)
Pre 677.06 ± 662 836.3 ± 576 P=0.4
Post 702.6 ± 796 1140.3 ± 792
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the ROVA study. This study showed that in patients with 
congestive heart failure CHF, LV dysfunction and chronic 
AF undergoing permanent pacing, RVOT and dual-site RV 
pacing shorten but do not normalize paced QRS duration 
and do not consistently improve quality of life QOL or other 
clinical outcomes after three months as compared with RVA 
pacing. In contrast, Mera et al.,[8] reported that in 10 patients 
with LV dysfunction, who underwent AV junction ablation, 
LVEF was higher after two months of high septal RVOT 
than RV apex pacing. More recently, Tse et al.,[9]randomized 
24 patients, none of whom had CHF or LVEF <50%, to 
long-term RVOT or RV apex pacing. Between months 6 
and 18 after initiation of pacing, LVEF declined (55% ± 3% 
to 47% ± 3%) and myocardial perfusion defects increased 
during RV apex but not RVOT pacing.
The purpose of our study was to assess if RV septal 
pacing, compared to RV apex pacing, would impact cardiac 
function using the parameter BNP. It is well known that 
different cardiac pacing modes have different effects on 
patients’ hemodynamics; however, it is not yet known how 
BNP levels change in different cardiac pacing sites.
In this small randomized study, we showed that plasma 
concentrations of BNP were higher in patients with a VVI 
pacing mode compared with a DDD mode [P=0.02, see 
Figure 1] which is consistent with previously published 
studies.[21,22]Our main result showed no significant differences 
between pacing sites and concluded that hemodynamic 
improvement could be substantially influenced by pacing 
mode, more than by pacing site.
Limitations of the study
The main limitation of this study was the small number 
of patients. Potential limitations in the study design may 
have affected our results. Beneficial or deleterious effects 
of longer pacing durations from alternative RV sites could 
not be addressed by this study. The present data is also 
limited by the fact that the study patients did not undergo 
follow-up echocardiograms and 6-min walk tests.
CONCLUSIONS
The present study showed no significant differences 
between pacing sites and concluded that hemodynamic 
improvement could be substantially influenced by pacing 
mode, more than by pacing site.
REFERENCES
1.  Leclercq C, Gras D, Le Helloco A, Nicol L, Mabo P, Daubert C.Hemodynamic 
importance of preserving the normal sequence of ventricular activation in 
permanent cardiac pacing. Am Heart J1995;129:1133-41.
2.  Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H,et al. 
Dual chamber and VVI implantable defibrillator trial investigators. Dual-
chamber pacing or ventricular backup pacingin patients with an implantable 
defibrillator: The Dual Chamberand VVI Implantable Defibrillator 
(DAVID) trial. JAMA 2002;288:3115-23.
3.  Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, FreedmanRA, 
Lee KL, et al. Mode Selection Trial Investigators.Adverse effect of 
ventricular pacing on heart failure and atrial fibrillationamong patients with 
normal baseline QRS duration in aclinical trial of pace maker therapy for 
sinus node dysfunction. Circulation 2003;107:2932-7.
4.  Thambo JB, Bordachar P, Garrigue S, Lafitte S, Sanders P, Reuter S, et al. 
Detrimental ventricular remodeling in patientswith congenital complete 
heart block and chronic right ventricularapical pacing. Circulation 
2004;110:3766-72.
5.  Littman L, Symanski JD. Hemodynamic implications of left bundlebranch 
block. J Electrocardiol 2000;33(Suppl.):115-21.
6.  Shenkman HJ, Pampati V, Khandelwal AK, McKinnon J, Nori D, Kaatz 
S, et al. Congestive heartfailure and QRS duration: Establishing prognosis 
study. Chest 2002;122:528-34.
7.  Hesse B, Diaz LA, Snader CE, Blackstone EH, Lauer MS. Complete 
bundle branch blockas an independent predictor of all-cause mortality: 
Report of 7,073 patients referred for nuclear exercise testing. Am J Med 
2001;110:253-9.
8.  Mera F, DeLurgio DB, Patterson RE, Merlino JD, Wade ME, LeonAR. A 
comparison of ventricular function during high right ventricularseptal and 
apical pacing after His-bundle ablation for refractoryatrial fibrillation. Pacing 
Clin Electrophysiol 1999;22:1234-9.
9.  Tse HF, Yu C, Wong KK, Tsang V, Leung YL, Ho WY, et al. Functional 
abnormalities in patients with permanent right ventricularpacing: The 
effect of sites of electrical stimulation. J Am CollCardiol 2002;40:1451-8.
10.  Wang R, Li X, Jang W, Liu Z, Yang X, Xiao C, et al. Blood B type natriuretic 
peptide changes in different periods and different cardiac pacing modes. 
Int Heart J 2005;46:1015-22.
11.  Wong GC, Ayas NT. Clinical approaches to the diagnosis of acute heart 
failure. Curr Opin Cardiol 2007;22:207-13.
12.  Horio H, Tsutamoto T, Ishimoto N, Minai K, Yokohama H, Nozawa 
M, et al. Plasma brain natriuretic peptide as a biochemical marker 
for atrioventricular sequence in patints with pacemakers. Pacing Clin 
Electrophysiol1999;22:282-90.
13.  Wu X, Seino Y, Ogura H, Fukuma N, Katoh T, Takano T. Plasma natriuretic 
peptide levels and daily physical activity in patients with pacemaker 
implantation. Jpn Heart J 2001;42:471-82.
14.  Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, 
Vesterlund T, et al. Long-term follow-up of patients from a randomized 
trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 
1997;350:1210-6.
15.  Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, et al. Effects 
of physiologic pacing versus ventricular pacing on the risk of stroke and 
death due to cardiovascular causes. Canadian Trial of Physiologic Pacing 
Investigators. N Engl J Med 2000;342:1385-91.
16.  Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, et al. 
Ventricular pacing ordual-chamber pacing for sinus-node dysfunction. N 
Engl J Med2002;346:1854-62. 
17.  Bourke JP, Hawkins T, Keavey P, Tynan M, Jamieson S, Behulova R, et al. 
Evolution of ventricular function during permanent pacing from either 
right ventricular apex or outflow tract following AV-junctional ablation for 
atrial fibrillation. Europace 2002;4:219-28.
18.  Stambler BS, Ellenbogen K, Zhang X, Levine P, Porter TR, Zhang X. 
Right ventricular outflow versus apical pacing in pacemaker patients with 
congestive heart failure and atrial fibrillation. J Cardiovasc Electrophysiol 
2003;14:1180-6.
19.  de Cock CC, Giudici MC, Twisk JW. Comparison of the haemodynamic 
effects of right ventricular outflow-tract pacing with right ventricular apex 
pacing: A quantitative review. Europace 2003;5:275-8. 
20.  Victor F, Mabo P, Mansour H, Pavin D, Kabalu G, de Place C, et al. A 
randomized comparison of permanent septal pacing versus apical right 
ventricular pacing. J Cardiovasc Electrophysiol 2006;17:1-5.109 Journal of Cardiovascular Disease Research Vol. 2 / No 2
Nikoo, et al.: Effect of pacing sites on plasma natriuretic peptides levels
21.  H¨ oijer CJ, Brandt J, Willenheimer R, Juul-M¨ oller S, Bostr¨om PA. Improved 
cardiac function and quality of life following upgrade to dual chamber pacing 
after long-term ventricular stimulation. EurHeart J 2002;23:490-7.
22.  Naegeli B, Kurz DJ, Koller D, Straumann E, Furrer M, Maurer D, et al. 
Single-chamber ventricular pacing increases markers of left ventricular 
dysfunction compared with dual-chamber pacing. Europace 2007;9:194-9.
Author Help: Reference checking facility
The manuscript system (www.journalonweb.com) allows the authors to check and verify the accuracy and style of references. The tool checks 
the references with PubMed as per a predefined style. Authors are encouraged to use this facility, before submitting articles to the journal.
•	 The style as well as bibliographic elements should be 100% accurate, to help get the references verified from the system. Even a 
single spelling error or addition of issue number/month of publication will lead to an error when verifying the reference. 
•	 Example of a correct style
  Sheahan P, O’leary G, Lee G, Fitzgibbon J. Cystic cervical metastases: Incidence and diagnosis using fine needle aspiration biopsy. 
Otolaryngol Head Neck Surg 2002;127:294-8. 
•	 Only the references from journals indexed in PubMed will be checked. 
•	 Enter each reference in new line, without a serial number.
•	 Add up to a maximum of 15 references at a time.
•	 If the reference is correct for its bibliographic elements and punctuations, it will be shown as CORRECT and a link to the correct 
article in PubMed will be given.
•	 If any of the bibliographic elements are missing, incorrect or extra (such as issue number), it will be shown as INCORRECT and link to 
possible articles in PubMed will be given. 
How to cite this article: Nikoo MH, Ghaedian MM, Kafi M, Fakhrpour 
A, Jorat MV, Pakfetrat M, Ostovan M, Emkanjoo Z. Effects of right 
ventricular septal versus apical pacing on plasma natriuretic peptide 
levels. J Cardiovasc Dis Res 2011;2:104-9.
Source of Support: Nil, Conflict of Interest: None declared.